These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31549625)

  • 1. Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects
.
    Yokote K; Suzuki A; Li Y; Matsuoka N; Teramoto T
    Int J Clin Pharmacol Ther; 2019 Dec; 57(12):575-589. PubMed ID: 31549625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive　- Results From a Randomized, Placebo-Controlled, Dose-Ranging Study.
    Yokote K; Kanada S; Matsuoka O; Sekino H; Imai K; Tabira J; Matsuoka N; Chaudhuri S; Teramoto T
    Circ J; 2017 Sep; 81(10):1496-1505. PubMed ID: 28539539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.
    Gumbiner B; Joh T; Liang H; Wan H; Levisetti M; Vana AM; Shelton DL; Forgues P; Billotte S; Pons J; Baum CM; Garzone PD
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
    Fazio S; Robertson DG; Joh T; Wan H; Riel T; Forgues P; Baum CM; Garzone PD; Gumbiner B
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29057618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
    Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
    Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301].
    Wang EQ; Plotka A; Salageanu J; Sattler C; Yunis C
    Cardiovasc Ther; 2017 Oct; 35(5):. PubMed ID: 28636184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia.
    Ballantyne CM; Neutel J; Cropp A; Duggan W; Wang EQ; Plowchalk D; Sweeney K; Kaila N; Vincent J; Bays H
    Am J Cardiol; 2015 May; 115(9):1212-21. PubMed ID: 25784512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.
    Ridker PM; Tardif JC; Amarenco P; Duggan W; Glynn RJ; Jukema JW; Kastelein JJP; Kim AM; Koenig W; Nissen S; Revkin J; Rose LM; Santos RD; Schwartz PF; Shear CL; Yunis C;
    N Engl J Med; 2017 Apr; 376(16):1517-1526. PubMed ID: 28304227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
    Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
    J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9.
    Baruch A; Luca D; Kahn RS; Cowan KJ; Leabman M; Budha NR; Chiu CPC; Wu Y; Kirchhofer D; Peterson A; Davis JC; Tingley WG
    Clin Cardiol; 2017 Jul; 40(7):503-511. PubMed ID: 28326559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
    Ridker PM; Revkin J; Amarenco P; Brunell R; Curto M; Civeira F; Flather M; Glynn RJ; Gregoire J; Jukema JW; Karpov Y; Kastelein JJP; Koenig W; Lorenzatti A; Manga P; Masiukiewicz U; Miller M; Mosterd A; Murin J; Nicolau JC; Nissen S; Ponikowski P; Santos RD; Schwartz PF; Soran H; White H; Wright RS; Vrablik M; Yunis C; Shear CL; Tardif JC;
    N Engl J Med; 2017 Apr; 376(16):1527-1539. PubMed ID: 28304242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development.
    Udata C; Garzone PD; Gumbiner B; Joh T; Liang H; Liao KH; Williams JH; Meng X
    J Clin Pharmacol; 2017 Jul; 57(7):855-864. PubMed ID: 28181260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials.
    Ridker PM; Amarenco P; Brunell R; Glynn RJ; Jukema JW; Kastelein JJ; Koenig W; Nissen S; Revkin J; Santos RD; Schwartz PF; Yunis C; Tardif JC;
    Am Heart J; 2016 Aug; 178():135-44. PubMed ID: 27502861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
    Nissen SE; Dent-Acosta RE; Rosenson RS; Stroes E; Sattar N; Preiss D; Mancini GB; Ballantyne CM; Catapano A; Gouni-Berthold I; Stein EA; Xue A; Wasserman SM; Scott R; Thompson PD;
    Clin Cardiol; 2016 Mar; 39(3):137-44. PubMed ID: 26946077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
    J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
    Stroes E; Guyton JR; Lepor N; Civeira F; Gaudet D; Watts GF; Baccara-Dinet MT; Lecorps G; Manvelian G; Farnier M;
    J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27625344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.